Myasthenia gravis: trials for referral
136 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
136 trials shown
Phase 369 sites
RecruitingCanada, China, Germany, Spain, France, Georgia
NCT07463521
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
UCB Biopharma SRL
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 361 sites
RecruitingChina, Germany, Spain, France, Georgia, Greece
NCT07465289
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
UCB Biopharma SRL
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govNo phase20 sites
RecruitingGermany, Denmark, Spain, France, Italy
NCT07323316
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Ad scientiam
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 2/39 sites
RecruitingUnited Kingdom, Italy, South Korea, Poland, United States
NCT06055959
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
UCB Biopharma SRL
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 3102 sites
RecruitingAustralia, Belgium, Canada, China, Czechia, Germany
NCT04951622
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
Not yet recruitingChina
NCT07917923
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
Daishi Tian
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 230 sites
RecruitingBelgium, Germany, Spain, Greece, Italy, Japan
NCT07673627
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
argenx
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 2/319 sites
RecruitingJapan, Netherlands, Poland, United States
NCT05265273
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 2/325 sites
By invitation onlyAustria, Belgium, Canada, Czechia, Germany, Spain
NCT05374590
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
argenx
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 342 sites
RecruitingAustria, Switzerland, Germany, Spain, Israel, Italy
NCT07217587
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 355 sites
RecruitingAustria, Bulgaria, Czechia, Germany, Denmark, Spain
NCT07647510
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Dianthus Therapeutics
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 214 sites
RecruitingPoland, United States
NCT07673744
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
TG Therapeutics, Inc.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 18 sites
RecruitingUnited States
NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 216 sites
RecruitingArgentina, Brazil, Spain, France, United Kingdom, Italy
NCT06987539
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Amgen
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingChina
NCT07622342
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Guangdong Hengrui Pharmaceutical Co., Ltd
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 31 site
RecruitingCanada
NCT06765161
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Clinique Neuro-Outaouais
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 114 sites
RecruitingUnited States
NCT06626919
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
Kite, A Gilead Company
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 3159 sites
RecruitingArgentina, Australia, Belgium, Bulgaria, Canada, Switzerland
NCT06463587
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 310 sites
RecruitingChina
NCT07596784
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Pre-treatment window Registry sentence: “Untreated thymic malignancy/carcinoma/thymoma excluded.”
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 1/217 sites
RecruitingUnited States
NCT06359041
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingAustralia, Canada, United States
NCT07304154
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Kite, A Gilead Company
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07022197
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Tianjin Medical University General Hospital
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 36 sites
By invitation onlyUnited Kingdom, Italy, South Korea, Poland
NCT06435312
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
UCB Biopharma SRL
Registry updated 2 Oct 2026
Registry record: ClinicalTrials.govPhase 2/322 sites
RecruitingAustralia, Belgium, Canada, Switzerland, Czechia, Germany
NCT06392386
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
argenx
Registry updated 28 Sept 2026
Registry record: ClinicalTrials.govPhase 239 sites
RecruitingBelgium, Germany, Spain, Greece, Italy, Japan
NCT07284420
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Registry updated 24 Sept 2026
Registry record: ClinicalTrials.govPhase 12 sites
Not yet recruitingChina
NCT07818291
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
Shanghai Lanyi Therapeutics Co., Ltd.
Registry updated 14 Sept 2026
Registry record: ClinicalTrials.govPhase 49 sites
RecruitingFrance
NCT07072988
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
Centre Hospitalier Universitaire de Nice
Registry updated 3 Sept 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingChina
NCT07215650
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Candid Therapeutics
Registry updated 2 Sept 2026
Registry record: ClinicalTrials.govPhase 33 sites
RecruitingUnited States
NCT07215949
Zilucoplan for Severe gMG Exacerbations
Miriam Freimer
Registry updated 28 Aug 2026
Registry record: ClinicalTrials.govPhase 240 sites
RecruitingBelgium, Denmark, Spain, France, Georgia, Italy
NCT06414954
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NMD Pharma A/S
Registry updated 21 Aug 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States52 open trials
- China42 open trials
- Italy32 open trials
- France23 open trials
- Poland22 open trials
- Germany22 open trials
- Spain21 open trials
- Japan10 open trials
- United Kingdom10 open trials
- Belgium10 open trials
- Canada8 open trials
- Denmark8 open trials
- Netherlands8 open trials
- Greece7 open trials
- Georgia6 open trials
- Australia6 open trials
- South Korea5 open trials
- Czechia5 open trials
- Taiwan5 open trials
- Austria5 open trials
- Israel5 open trials
- Hungary4 open trials
- Serbia4 open trials
- Bulgaria3 open trials
- Brazil3 open trials
- Argentina3 open trials
- Mexico2 open trials
- Switzerland2 open trials
- Romania2 open trials
- Sweden2 open trials
- Saudi Arabia2 open trials
- Portugal1 open trial
- Ukraine1 open trial
- Latvia1 open trial
- Türkiye1 open trial
- India1 open trial
- Russia1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, China
4 trials · 9 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Closed for recruitment
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
NCT07478172 · No phase · United States
Source: ClinicalTrials.govOpened for recruitment
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
NCT07323316 · No phase · Germany, Denmark, Spain, France, Italy
Source: ClinicalTrials.govOpened for recruitment
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510 · Phase 3 · Austria, Bulgaria, Czechia, Germany, Denmark, Spain
Source: ClinicalTrials.govClosed for recruitment
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702 · Phase 2 · Australia, United Kingdom, Poland, United States
Source: ClinicalTrials.govOpened for recruitment
NCT07465289 · Phase 3 · China, Germany, Spain, France, Georgia, Greece
Source: ClinicalTrials.govOpened for recruitment
NCT07221838 · Phase 4 · Germany, Italy, Japan, United States
Source: ClinicalTrials.govClosed for recruitment
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580 · Phase 3 · Argentina, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
NCT06435312 · Phase 3 · United Kingdom, Italy, South Korea, Poland
Source: ClinicalTrials.govClosed for recruitment
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159 · Phase 2 · Argentina, Canada, Czechia, Denmark, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT05644561 · Phase 3 · Switzerland, Spain, France, Italy, Japan, Netherlands
Source: ClinicalTrials.govClosed for recruitment
NCT07221838 · Phase 4 · Germany, Italy, Japan, United States
Source: ClinicalTrials.govOpened for recruitment
NCT05644561 · Phase 3 · Switzerland, Spain, France, Italy, Japan, Netherlands
Source: ClinicalTrials.govOpened for recruitment
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159 · Phase 2 · Argentina, Canada, Czechia, Denmark, Spain, France
Source: ClinicalTrials.govOpened for recruitment
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580 · Phase 3 · Argentina, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govOpened for recruitment
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702 · Phase 2 · Australia, United Kingdom, Poland, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07465289 · Phase 3 · China, Germany, Spain, France, Georgia, Greece
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510 · Phase 3 · Austria, Bulgaria, Czechia, Germany, Denmark, Spain
Source: ClinicalTrials.govPhase changed: No phase → Phase 2/3
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
NCT07403188 · Phase 2/3 · Germany, United States
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 2/3Ended 5 Oct 2026
Completed14 participants
NCT06149559
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Early Phase 1Ended 23 Sept 2026
Withdrawn before start0 participants
NCT07583030
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
Reason given: pipeline strategy change
Phase 3Ended 7 Aug 2026
Stopped early233 participants
NCT05403541
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Reason given: Sponsor Decision
Phase 3Ended 31 Jul 2026
Completed200 participants
NCT04225871
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
No phaseEnded 30 Jun 2026
Completed60 participants
NCT06707727
Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis
Phase 3Ended 20 Apr 2026
Completed152 participants
2024-512258-91-00
Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)
No phaseEnded 11 Feb 2026
Stopped early9 participants
NCT06965309
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
Reason given: Change of registrant
No phaseEnded 31 Dec 2025
Completed19 participants
NCT07649187
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
Phase 3Ended 29 Dec 2025
Completed15 participants
NCT06764160
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
No phaseEnded 18 Dec 2025
Completed100 participants
NCT07319689
Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients
Phase 3Ended 6 Oct 2025
No phaseEnded 30 Sept 2025
Completed150 participants
NCT06718855
Cognitive Functioning in People With Myasthenia Graivs: Impact on Daily Life Activities, Work, Disability and Quality of Life
Phase 1Ended 24 Jul 2025
Completed7 participants
NCT05451212
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Phase 1Ended 17 Jun 2025
Withdrawn before start0 participants
NCT06869278
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Reason given: Legend discontinues the development of the IMP.
No phaseEnded 31 May 2025
Phase 2Ended 30 Apr 2025
Stopped early2 participants
NCT04226170
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
Reason given: lack of enrollment
No phaseEnded 15 Mar 2025
Completed83 participants
NCT05992025
Digital Phenotyping and Lifestyle Intervention in Patients with Myasthenia Gravis
No phaseEnded 5 Mar 2025
Completed62 participants
NCT06436768
Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis
No phaseEnded 3 Mar 2025
Phase 3Ended 3 Feb 2025
Completed31 participants
NCT06471361
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
Show more
No phaseEnded 10 Jan 2025
Completed236 participants
NCT05566964
Descriptive Analysis of Real-world Data Collected with ME&MGopen
No phaseEnded 9 Jan 2025
Completed77 participants
NCT07291713
Psychological Health and Adverse Childhood Experiences in Myasthenia Gravis: Online Mental Health BMI Learning Program
No phaseEnded 31 Dec 2024
Completed16 participants
NCT04678115
Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis
Phase 3Ended 31 Dec 2024
No phaseEnded 25 Dec 2024
Completed23 participants
NCT06158815
Investigation of the Effects of Proprioceptive Neuromuscular Facilitation Exercises in Patients With Myasthenia Gravis
Phase 3Ended 12 Dec 2024
No phaseEnded 6 Nov 2024
Completed800 participants
NCT07022028
Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia Gravis
No phaseEnded 1 Nov 2024
Completed13 participants
NCT05979688
Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis
Phase 3Ended 23 Oct 2024
No phaseEnded 9 Sept 2024
Completed30 participants
NCT05890833
The Risk of Falls Index for Patients With Neuromuscular Disorders
Phase 3Ended 2 Sept 2024
Stopped early188 participants
NCT04963270
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Reason given: Sponsor decided to halt development of satralizumab in generalized myasthenia gravis and discontinued further dosing with the study drug (while the OLE period was ongoing) upon reviewing the primary results (DB period).
No phaseEnded 31 Jul 2024
Completed231 participants
NCT07472777
Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis
No phaseEnded 31 May 2024
No phaseEnded 30 Apr 2024
Phase 3Ended 26 Apr 2024
Completed111 participants
NCT05332210
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Phase 3Ended 23 Apr 2024
Phase 2Ended 3 Apr 2024
Stopped early70 participants
NCT05218096
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Reason given: Sponsor decision
Early Phase 1Ended 31 Mar 2024
Completed19 participants
NCT04431895
Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study
Phase 2Ended 31 Jan 2024
Withdrawn before start0 participants
NCT04982289
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
Reason given: Sponsor decision to terminate program
Phase 3Ended 25 Jan 2024
Completed165 participants
NCT04650854
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
- Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions. · Therapeutic advances in neurological disorders, 2026
Phase 2Ended 30 Dec 2023
No phaseEnded 16 Dec 2023
Completed10 participants
NCT06256172
Medlink for Diagnosing of Diabetes Mellitus, COPD, CHF, Myasthenia Gravis and Hypertension
No phaseEnded 1 Dec 2023
Not medical advice. fetched 10 Nov 2026